Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on Monday. The Dow traded up 0.29% to 34,676.52 while the NASDAQ rose 1.16% to 13,920.60. The S&P...

Nasdaq Rises Over 1%; Hostess Brands Shares Spike Higher

September 11, 2023

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Intraday Session

September 11, 2023

Via Benzinga

Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) Near the Top of Equities by Percentage Gain on 9/11

September 11, 2023

Via Investor Brand Network

9 Analysts Have This to Say About Crinetics Pharmaceuticals

August 31, 2023

Via Benzinga

Analyst Expectations for Crinetics Pharmaceuticals's Future

August 09, 2023

Via Benzinga

Where Crinetics Pharmaceuticals Stands With Analysts

June 08, 2023

Via Benzinga

Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session

September 11, 2023

Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study...

Via Benzinga

Why Shares of Crinetics Pharmaceuticals Are Jumping Monday

September 11, 2023

The biotech company reported positive phase 3 trial results.

Via The Motley Fool

Gold Edges Higher; Virco Manufacturing Shares Surge After Q2 Results

September 11, 2023

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 80 points on Monday. The Dow traded up 0.40% to 34,715.88 while the NASDAQ rose 0.58% to 13,841.50. The S&P...

Via Benzinga

Topics Stocks

The Latest Analyst Ratings for Crinetics Pharmaceuticals

April 24, 2023

Via Benzinga

Crinetics Pharma's Investigational Candidate Shows Promise In Rare Type Of Hormonal Disorder

September 11, 2023

On Sunday, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) said its Phase 3 PATHFNDR-1 study evaluating paltusotine met the primary and secondary

Via Benzinga

Crinetics Pharmaceuticals Just Scored A Much-Needed Win And Soared 71%

September 11, 2023

The company is working on a treatment for a growth hormone disorder.

Via Investor's Business Daily

US Stocks Open Higher; Dow Jumps 150 Points

September 11, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.46% to 34,736.26 while the NASDAQ rose 0.94% to...

Via Benzinga

Topics Stocks

Why Is Nuwellis (NUWE) Stock Down Today?

September 11, 2023

Nuwellis (NUWE) stock is taking a beating on Monday despite a lack of news or increased trading activity for the medical device company.

Tenon Medical (TNON) stock is falling on Monday after the surgical implant company announced a proposed public offering for its shares.

12 Health Care Stocks Moving In Monday's Pre-Market Session

September 11, 2023

Via Benzinga

Why Is Tenon Medical (TNON) Stock Down 30% Today?

September 11, 2023

Versus Systems (VS) stock is rising higher on Monday as the business software company's shares experience heavy trading this morning.

Why Is Versus Systems (VS) Stock Up 17% Today?

September 11, 2023

Crinetics Pharmaceuticals (CRNX) stock is on the rise Monday after the company announced positive clinical trial results.

Why Tenon Medical Shares Are Trading Lower By 34%; Here Are 20 Stocks Moving Premarket

September 11, 2023

Gainers

Via Benzinga

Why Is Crinetics Pharmaceuticals (CRNX) Stock Up 64% Today?

September 11, 2023

We're starting off the workweek right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

September 11, 2023

Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session

September 11, 2023

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly

September 10, 2023

Biotech Stock Crinetics Pharmaceuticals Positioned For Success In Chronic Endocrine Disorder Treatment, Says Analyst

August 31, 2023

Oppenheimer initiated coverage on Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) with an Outperform rating

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023

August 31, 2023

Via Benzinga

Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 08, 2023

New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023

June 21, 2023

Endocrine Society President to Present Crinetics CEO with John D. Baxter Prize for Entrepreneurship

Crinetics to Highlight Broad Pipeline at ENDO 2023

June 09, 2023

Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 04, 2023